Cannabinoid Encyclopedia

Focused research review

How does CBG interact with biological targets?

CBG can interact with several biological targets in laboratory and animal research. That maps possible mechanisms, but it does not show a health benefit in people.

Updated July 2026 24 research sources Mostly early-stage research

The short answer

What is the bottom line?

CBG target biology is a mechanism map, not proof of a health effect. 1 2 3

The approved sources examine receptor and signaling activity, including alpha-2 adrenergic and 5-HT1A-related findings. Target activity can help explain why a study is plausible, but it cannot predict a clinical outcome without human outcome research. 1 2 3

What this means: A study showing that CBG binds, activates, blocks, or changes a target should be read as biology. It does not show that a person will experience a specific benefit, dose response, or safety outcome. 1 2 3

How to read this answer: A study showing that CBG binds, activates, blocks, or changes a target should be read as biology. It does not show that a person will experience a specific benefit, dose response, or safety outcome. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBG and biological targets.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    CBG target studies ask how the compound interacts with receptors, channels, and signaling systems. 1

  2. 2

    Mechanistic plausibility is not the same as clinical efficacy. 2

  3. 3

    Different targets, model systems, concentrations, and formulations can produce different biological observations. 3

Choose your question

What do you want target research to answer?

Target studies explain possible biology. They do not answer a human outcome question by themselves.

  1. 01Reader question

    Which targets are being studied?

    See the receptor and signaling questions represented in the current source set.

    Explore the evidence
  2. 02Reader question

    Does a mechanism prove CBG works?

    No. Open the evidence section for the difference between biological plausibility and human outcomes.

    Explore the evidence
  3. 03Reader question

    Where can I read the original papers?

    Use the source library to open PubMed or DOI records.

    Explore the evidence

Research areas

What researchers studied about CBG and biological targets

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Receptor, target, metabolic, or pharmacology mechanisms

This part of the literature focuses on Receptor, target, metabolic, or pharmacology mechanisms. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 4

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

4 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

11 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

9 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CBG and biological targets is not one kind of study. This source set includes 9 narrative or expert reviews, 8 animal studies, 3 cell or laboratory studies, and 2 clinical studies in people. 3

The recorded populations or models include people or patients (9 sources), animal models (7 sources), and cells or tissue models (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is receptor, target, metabolic, or pharmacology mechanisms (24 sources). Closely related outcome names can still describe different measurements. 5

The CBG and biological targets source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms. 1

Study type
animal study
Population or model
people or patients
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

animal study

Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms. 2

Study type
animal study
Population or model
animal models
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

clinical study in people

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms. 3

Study type
clinical study in people
Population or model
people or patients
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

narrative or expert review

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

animal study

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms. 5

Study type
animal study
Population or model
animal models
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

Research on CBG and biological targets should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What biological targets has CBG been linked to?

The source set includes alpha-2 adrenergic, 5-HT1A-related, cannabinoid-receptor, and other target or signaling research. Each finding depends on the experimental system. 7

Does CBG target activity prove a health benefit?

No. A target finding can make a health question worth studying, but controlled human outcome studies are needed to test whether it changes symptoms or health measures. 8

Why do CBG mechanism studies differ?

Studies can use different cell types, animal models, concentrations, compounds, and methods. Those choices can change the observed target activity. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. animal study; mechanism-focused research PubMed 20002104 DOI 10.1111/j.1476-5381.2009.00515.x
  2. 2
    Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. animal study; mechanism-focused research PubMed 37305529 DOI 10.3389/fphar.2023.1183019
  3. 3
    Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. clinical study in people; evidence still limited PubMed 39003387 DOI 10.1038/s41598-024-66879-0
  4. 4
    Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited PubMed 39598860 DOI 10.3390/molecules29225471
  5. 5
    Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. animal study; mechanism-focused research PubMed 25269802 DOI 10.1093/carcin/bgu205
  6. 6
    Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
  7. 7
    The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited PubMed 33998900 DOI 10.1089/can.2020.0105
  8. 8
    Acute Cannabigerol Administration Lowers Blood Pressure in Mice. clinical study in people; evidence still limited PubMed 35615681 DOI 10.3389/fphys.2022.871962
  9. 9
    Cannabinoid hyperemesis syndrome. narrative or expert review; evidence still limited PubMed 22150623 DOI 10.2174/1874473711104040241
  10. 10
    Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. narrative or expert review; evidence still limited PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
  11. 11
    Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
  12. 12
    Non-psychotropic phytocannabinoid interactions with voltage-gated sodium channels: An update on cannabidiol and cannabigerol. narrative or expert review; evidence still limited PubMed 36439273 DOI 10.3389/fphys.2022.1066455
See all 24 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 39598860
  2. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 1 linked research note PubMed 21749363
  3. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33998900
  4. Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38885660
  5. The Pharmacological Case for Cannabigerol. narrative or expert review; evidence still limited / 1 linked research note PubMed 33168643
  6. Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 40967679
  7. Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 28120231
  8. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. animal study; mechanism-focused research / 1 linked research note PubMed 25269802
  9. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. narrative or expert review; evidence still limited / 1 linked research note PubMed 42105814
  10. Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. animal study; mechanism-focused research / 1 linked research note PubMed 40540228
  11. Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. animal study; mechanism-focused research / 1 linked research note PubMed 40326034
  12. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. clinical study in people; evidence still limited / 1 linked research note PubMed 39003387
  13. The Origin and Biomedical Relevance of Cannabigerol. narrative or expert review; evidence still limited / 1 linked research note PubMed 35887277
  14. Cannabinoid hyperemesis syndrome. narrative or expert review; evidence still limited / 1 linked research note PubMed 22150623
  15. The Pharmacology of Cannabinoids in Chronic Pain. narrative or expert review; evidence still limited / 1 linked research note PubMed 40046175
  16. Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. animal study; mechanism-focused research / 1 linked research note PubMed 37305529
  17. Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models. animal study; mechanism-focused research / 1 linked research note PubMed 41155621
  18. Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40706771
  19. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. animal study; mechanism-focused research / 1 linked research note PubMed 20002104
  20. Acute Cannabigerol Administration Lowers Blood Pressure in Mice. clinical study in people; evidence still limited / 1 linked research note PubMed 35615681
  21. Cannabigerol reverses mechanical allodynia through α2A-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy. animal study; mechanism-focused research / 1 linked research note PubMed 41435878
  22. Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 29977202
  23. Metabolites of Cannabigerol Generated by Human Cytochrome P450s Are Bioactive. animal study; mechanism-focused research / 1 linked research note PubMed 36223199
  24. Non-psychotropic phytocannabinoid interactions with voltage-gated sodium channels: An update on cannabidiol and cannabigerol. narrative or expert review; evidence still limited / 1 linked research note PubMed 36439273